NASDAQ:ARDXArdelyx Stock Price, Forecast & News

$6.93

-0.07 (-1.00 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$6.70

Now: $6.93▼

$7.13

50-Day Range

$6.44

MA: $7.28▼

$8.07

52-Week Range

$2.10

Now: $6.93▼

$8.81

Volume867,987 shs

Average Volume784,734 shs

Market Capitalization$616.28 million

P/E RatioN/A

Dividend YieldN/A

Beta1.89

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Ardelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Ardelyx has a potential upside of 73.2% from its current price of $6.93.
Amount of Analyst Coverage
Ardelyx has received no research coverage in the past 90 days.

2.7 Community Rank

Outperform Votes
Ardelyx has received 474 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ardelyx has received 419 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ardelyx has received 53.08% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote “Outperform” if you believe ARDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ardelyx does not currently pay a dividend.
Dividend Growth
Ardelyx does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $484,119.00 in company stock.
Percentage Held by Insiders
Only 15.31% of the stock of Ardelyx is held by insiders.
Percentage Held by Institutions
86.08% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Ardelyx are expected to grow in the coming year, from ($1.05) to ($0.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ardelyx is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ardelyx is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ardelyx has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.57 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ARDX

Previous Symbol

CUSIPN/A

CIK1437402

Webwww.ardelyx.com

Phone510-745-1700

Debt

Debt-to-Equity Ratio0.26

Current Ratio9.76

Quick Ratio9.76

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.28 million

Price / Sales116.72

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.10 per share

Price / Book3.30

Profitability

EPS (Most Recent Fiscal Year)($1.47)

Net Income$-94,940,000.00

Net Margins-1,403.90%

Return on Equity-77.23%

Return on Assets-48.46%

Miscellaneous

Employees88

Outstanding Shares88,929,000

Market Cap$616.28 million

Next Earnings Date8/14/2020 (Estimated)

OptionableOptionable

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

How has Ardelyx's stock been impacted by COVID-19 (Coronavirus)?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARDX shares have increased by 15.9% and is now trading at $6.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ardelyx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ardelyx.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Ardelyx.

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.00. The biopharmaceutical company earned $1.21 million during the quarter, compared to the consensus estimate of $0.90 million. Ardelyx had a negative net margin of 1,403.90% and a negative return on equity of 77.23%. View Ardelyx's earnings history.

What price target have analysts set for ARDX?

5 brokerages have issued 12 month price targets for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 73.2% from the stock's current price. View analysts' price targets for Ardelyx.

Has Ardelyx been receiving favorable news coverage?

News headlines about ARDX stock have trended very negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ardelyx earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutArdelyx.

Who are some of Ardelyx's key competitors?

Some companies that are related to Ardelyx include Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), TG Therapeutics (TGTX), Pacira Biosciences (PCRX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Ligand Pharmaceuticals (LGND), SAGE Therapeutics (SAGE), Passage Bio (ZNTL), Zymeworks (ZYME), Xencor (XNCR), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH) and Madrigal Pharmaceuticals (MDGL). View all competitors.

What other stocks do shareholders of Ardelyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Gilead Sciences (GILD), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), BioCryst Pharmaceuticals (BCRX), ImmunoGen (IMGN), SCYNEXIS (SCYX), AbbVie (ABBV), NVIDIA (NVDA) and Rigel Pharmaceuticals (RIGL).

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:

Mr. Michael G. Raab, Pres, CEO & Director (Age 55, Pay $988k)
Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 56, Pay $596k)
Mr. David Rosenbaum, Chief Devel. Officer (Age 59, Pay $617.25k)
Mr. Keith Santorelli, Acting Principal Financial & Accounting Officer (Age 46)
Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 57)

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (7.22%), BlackRock Inc. (7.89%), Redmile Group LLC (4.39%), Ikarian Capital LLC (1.64%), State Street Corp (1.30%) and Geode Capital Management LLC (1.13%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, Michael Raab and Scott D Sandell. View institutional ownership trends for Ardelyx.

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Squarepoint Ops LLC, Redmile Group LLC, Invesco Ltd., Wexford Capital LP, UBS Group AG, DAFNA Capital Management LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Ardelyx company stock in the last year include Elizabeth A Grammer, Mark Kaufmann, and Michael Raab. View insider buying and selling activity for Ardelyx.

Which institutional investors are buying Ardelyx stock?

ARDX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., BlackRock Inc., Ikarian Capital LLC, Morgan Stanley, Morgan Stanley, State Street Corp, Bailard Inc., and AQR Capital Management LLC. View insider buying and selling activity for Ardelyx.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $6.93.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $616.28 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff